CHO Cell SUMF1 Co-expression for Phosphorylated Sulfatase Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing lysosomal sulfatase enzymes for treating lysosomal storage diseases face challenges in achieving high yields of active, highly phosphorylated enzymes due to inefficient secretion and immunogenicity issues, leading to suboptimal therapeutic effectiveness.
Innovation Solution
Engineering a CHO-K1 cell line derivative (G71) to co-express recombinant human sulfatase modifying factor 1 (SUMF1) and lysosomal sulfatase enzymes, such as N-acetylgalactosamine-6-sulfatase, to produce high yields of active, highly phosphorylated enzymes by preventing loss to the lysosomal compartment, thereby enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lysosomal sulfatase enzymes are produced in mammalian cell lines for enzyme replacement therapy, then therapeutic effectiveness is improved, but immunogenicity increases and productivity decreases
Solution Approach 1:
The patent modifies the glycosylation parameters of lysosomal sulfatase enzymes by expressing them in CHO cells that lack α1,3-galactosyltransferase activity. This parameter change prevents the addition of immunogenic α1,3-galactose residues while maintaining the therapeutic functionality of the enzymes, thereby resolving the contradiction between therapeutic effectiveness and immunogenicity.
Solution Approach 2:
The patent creates a simplified version of the native glycosylation pattern by producing enzymes with only high-mannose N-linked oligosaccharides, excluding complex and hybrid types. This copied simplified structure maintains therapeutic effectiveness while reducing immunogenicity and improving productivity.
2Reliability
If lysosomal sulfatase enzymes are highly phosphorylated to enhance targeting, then therapeutic effectiveness is improved, but secretion efficiency decreases
Solution Approach 1:
The patent optimizes the phosphorylation parameter by controlling the expression conditions and cell culture parameters to achieve high levels of mannose-6-phosphate modification without completely blocking secretion. The modified enzymes are successfully harvested from culture medium, resolving the contradiction between therapeutic effectiveness and ease of manufacture.
3Productivity
If endosomal acidification is prevented to improve enzyme secretion, then productivity is improved, but lysosomal routing is impaired
Solution Approach 1:
The patent uses the CHO cell's endosomal system as an intermediary mechanism that allows simultaneous achievement of high secretion and proper lysosomal routing. The cell's natural endosomal acidification process serves as a mediator that directs phosphorylated enzymes to both extracellular medium and lysosomes, resolving the contradiction between productivity and reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of therapeutic levels of active, highly phosphorylated lysosomal sulfatase enzymes, improving enzyme replacement therapy by ensuring effective targeting and reducing immunogenicity, thus enhancing treatment outcomes for lysosomal storage diseases.
Implementation Method 1
The cysteine to FGly post-translational enzyme activation occurs within the endoplasmic reticulum on unfolded sulfatases immediately after translation
Implementation Method 2
produce high yields of active, highly phosphorylated enzymes
Implementation Method 3
Mannose-6-phosphate is bound with high affinity and specificity by a receptor found on the surface of most cells
Data Source
AI summary
This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme.